Glutamate ionotropic receptor NMDA type subunit 2A (GluN2A) (GluN2A)

The Glutamate ionotropic receptor NMDA type subunit 2A (GluN2A) is a fundamental component of the N-methyl-D-aspartate (NMDA) receptor complex, which functions as a heterotetrameric ligand-gated ion channel in the central nervous system [1, 2]. This specific subunit contains the orthosteric binding site for glutamate, the brain's primary excitatory neurotransmitter, and requires the simultaneous binding of a co-agonist like glycine to the GluN1 subunit for channel activation [2, 4]. GluN2A-containing receptors are characterized by faster deactivation kinetics compared to GluN2B-containing receptors and play a vital role in synaptic maturation and the induction of long-term potentiation (LTP) [1, 3]. The developmental switch from GluN2B to GluN2A dominance is a hallmark of maturing neural circuits and is essential for normal cognitive development [3, 6]. Genetic mutations in the GRIN2A gene, which encodes this subunit, are linked to a variety of neurological disorders, including epilepsy-aphasia syndromes, schizophrenia, and intellectual disabilities [3, 5]. Pharmacological agents targeting this site include competitive antagonists designed to mitigate excitotoxic damage and positive allosteric modulators (PAMs) aimed at improving cognitive deficits [2, 6]. However, achieving therapeutic efficacy without inducing psychotomimetic side effects or dissociative states remains a significant challenge in drug development [4, 6].

Other names

GRIN2ANR2ANMDAR2AGlutamate [NMDA] receptor subunit epsilon-1N-methyl D-aspartate receptor subtype 2A

Drugs targeting the GluN2A glutamate site primarily act through competitive antagonism to block excitatory signaling or through allosteric modulation to either enhance (PAMs) or inhibit (NAMs) the channel's response to glutamate binding [2, 6].